title: Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing.
abstract: BACKGROUND
  The CO2 laser for cutaneous resurfacing has been associated with the reactivation of herpes simplex virus (HSV), causing delayed reepithelialization and scarring. Antiviral agents appear to be effective in reducing reactivation, however, the optimal therapeutic regimen has yet to be clearly defined.
  
  
  OBJECTIVE
  To assess the reactivation rates of HSV after CO2 laser resurfacing in patients who received prophylactic valacyclovir for either 10 or 14 days.
  
  
  METHODS
  One hundred twenty patients received valacyclovir 500 mg twice a day for either 10 or 14 days starting the day prior to facial laser resurfacing. Serology levels and consecutive Tzank preparations were obtained to determine past exposure to HSV and the presence of virus.
  
  
  RESULTS
  No patients in either group developed an HSV infection or had a recurrence.
  
  
  CONCLUSIONS
  These results support the use of valacyclovir in a 10- or 14-day regimen as a preventive agent against HSV outbreaks following facial laser resurfacing.
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, USA. fps@beeson.com
authors.forename: William H
authors.initials: WH
authors.lastname: Beeson
authors.forename: John D
authors.initials: JD
authors.lastname: Rachel
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D062109:Dermatologic Surgical Procedures; D005145:Face / Q000601:surgery*; D005260:Female; D006561:Herpes Simplex / Q000209:etiology / Q000517:prevention & control*; D018259:Herpesvirus 1, Human / Q000254:growth & development; D018258:Herpesvirus 2, Human / Q000254:growth & development; D006801:Humans; D053685:Laser Therapy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011355:Prodrugs / Q000627:therapeutic use*; D011446:Prospective Studies; D012008:Recurrence; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents; D011355:Prodrugs; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir